{
}
UBS has downgraded its recommendation for Scor from Buy to Neutral, maintaining a price target of 28.70 euros. The firm cites concerns over the company's high gearing compared to peers, disappointing organic capital generation, and the quality of its Solvency II ratio, which limit the potential for a higher payout ratio despite a 7.2% dividend yield.
UBS has downgraded Scor from Buy to Neutral, maintaining a target price of €28.70, citing limitations on dividend payouts due to high gearing, weak capital generation, and Solvency II ratio quality. The reinsurer, the fifth-largest globally, focuses on life and health, property & casualty, and investments, with a commitment to innovation and environmental sustainability. Challenges include sensitivity to natural catastrophes and currency fluctuations, alongside ongoing arbitration regarding the US life portfolio sale to Covea.
UBS has downgraded its recommendation on Scor from 'buy' to 'neutral', while keeping the target price at €28.7, indicating only a 4% upside potential for the shares. The downgrade is attributed to concerns over debt leverage, capital generation, and solvency quality, which limit the company's growth prospects.
Scor SE, France's leading reinsurer, has been downgraded from "buy" to "neutral" by UBS. The company's gross written premiums are divided into life and health reinsurance (50.8%) and non-life reinsurance (49.2%), which includes property and casualty as well as specialty reinsurance. Geographically, premiums are distributed with 12.6% from France, 45.9% from Europe, 23.8% from the Far East, and smaller percentages from North America, South America, Africa, and others.
UBS has downgraded its recommendation on Scor from 'buy' to 'neutral', while keeping the price target at 28.7 euros, indicating only a 4% upside potential for the shares. The downgrade is attributed to concerns over debt leverage, capital generation, and solvency quality, which limit the company's growth prospects.
UBS has downgraded its recommendation for Scor, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis and holds no responsibility for its content. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
The Biopharmaceutical Contract Manufacturing Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report analyzes market trends, competitive landscapes, and future growth prospects, highlighting key players such as Lonza Group Ltd. and Boehringer Ingelheim. The report also delves into market segmentation by contract type, product type, and therapeutic applications, providing valuable insights for stakeholders.
Pernod Ricard, the leading producer of premium wines and spirits, reported that 61.8% of its sales come from strategic international brands, with Absolut and Jameson being top sellers. The company operates 94 production sites globally, with sales distributed across Europe (28.3%), the Americas (28.8%), and other regions (42.9%).
ADQ has acquired a 63.26% stake in Aramex through a voluntary cash offer via Q Logistics Holding, valuing the courier firm at approximately Dh4.39 billion. The offer, priced at Dh3 per share, received a 40.57% acceptance from shareholders and follows ADQ's existing 22.69% stake through Abu Dhabi Ports Group. This move is part of ADQ's strategy to enhance its logistics portfolio, which includes various transport assets.
UBS has downgraded Scor SE from Buy to Neutral, setting a price target of €28.70, citing concerns over the company's dividend yield, which is projected at 7.2% for 2025. Despite a strong six-month return of 32.77%, the current yield of 4.75% is deemed insufficient compared to competitors, limiting growth potential. The analysis reflects a cautious outlook on Scor SE's market performance amid identified constraints on its payout ratio.
FRA
Country
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs downgrades scor to neutral citing dividend yield and capital concerns
10:31 31.03.2025
ubs downgrades scor to neutral amid concerns over dividend yield and capital generation
10:30 31.03.2025
ubs downgrades scor to neutral citing limited upside potential and risks
10:28 31.03.2025
scor downgraded to neutral by ubs amid premium breakdown analysis
10:27 31.03.2025
ubs downgrades scor to neutral citing limited upside potential and risks
10:25 31.03.2025
ubs downgrades recommendation for scor amid market analysis concerns
10:25 31.03.2025
biopharmaceutical contract manufacturing market poised for significant growth through 2032
10:01 31.03.2025
Pernod Ricard maintains strong market position in premium wines and spirits
United States Dollar
Pernod Ricard SA
ESP
SWE
FRA
NZL
IRL
CUB
GBR
USA
Émile Augier
Jameson Williams
Italicus
Jaeden Martell
Ricardo Darín
Lillete Dubey
St Hugo
George Lucas
Suze Rotolo
Eros Ramazzotti
Show more
09:41 31.03.2025
ADQ secures majority stake in Aramex to enhance logistics portfolio
09:38 31.03.2025
ubs downgrades scor se to neutral with price target of 28.70 euro
09:00 31.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
Danish Krone
Offshore Chinese Yuan
Mexican Peso
Indonesian Rupiah
South Korean Won
Malaysian Ringgit
Vietnamese Đồng
New Zealand Dollar
People: